Volume 8, Issue 31 (7-2018)
NCMBJ 2018, 8(31): 9-19 |
Back to browse issues page
Amir Amanzadeh 
, Vahid Molla-kazemiha , Mahdi Habibi-Anbouhi , Kayhan Azadmanesh , Seied Asadollah Mousavi , Mohsen Abolhassani , Mohammad Ali Shokrgozar
, Vahid Molla-kazemiha , Mahdi Habibi-Anbouhi , Kayhan Azadmanesh , Seied Asadollah Mousavi , Mohsen Abolhassani , Mohammad Ali Shokrgozar
National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran , shokrgozar1967@gmail.com
Abstract: (6656 Views)
Aim and Background:
The aim of this study was to enhance the synergistic effect of the "RA-FICZ" by adding anti CD44 monoclonal antibody (mAb), to induce myeloid differentiation and apoptosis in three patients with APL.
Materials and methods:
The anti-CD44 antibody concentrations of 5 to 25 μg/ml prepared and added to "RA-FICZ" complex and Isolated Cells from Patients.The antibody optimum concentration was determined then neutrophil maturation, apoptosis and expression of CD14 and CD11b were analyzed by flow cytometry.
Results:
Adding the different concentrations of CD44 mAb against CD44 improved the ability of promyelocytes differentiation and led to increased expression of CD11b and CD14 antigens more than two times. The apoptotic rate increased up to 66%.
Conclusion:
Additional studies and work on the animal models can lead to a reduction even elimination of the chemotherapy. This triple combination" can be candidate as a novel differentiation-inducing therapy in APL cells.
The aim of this study was to enhance the synergistic effect of the "RA-FICZ" by adding anti CD44 monoclonal antibody (mAb), to induce myeloid differentiation and apoptosis in three patients with APL.
Materials and methods:
The anti-CD44 antibody concentrations of 5 to 25 μg/ml prepared and added to "RA-FICZ" complex and Isolated Cells from Patients.The antibody optimum concentration was determined then neutrophil maturation, apoptosis and expression of CD14 and CD11b were analyzed by flow cytometry.
Results:
Adding the different concentrations of CD44 mAb against CD44 improved the ability of promyelocytes differentiation and led to increased expression of CD11b and CD14 antigens more than two times. The apoptotic rate increased up to 66%.
Conclusion:
Additional studies and work on the animal models can lead to a reduction even elimination of the chemotherapy. This triple combination" can be candidate as a novel differentiation-inducing therapy in APL cells.
Keywords: Acute Promyelocytic Leukemia, Anti CD44 Monoclonal Antibody, Retinoic Acid, Formylindolo (3, 2-B) Carbazole, Programmed Cell Death, Synergy.
Type of Study: Research Article |
Subject:
Cellular and molecular
Received: 2018/09/8 | Accepted: 2018/09/8 | Published: 2018/09/8
Received: 2018/09/8 | Accepted: 2018/09/8 | Published: 2018/09/8
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |